Responding to new research* that shows a ‘soft’ chemotherapy with targeted treatment is very effective in older patients with HER2...

9 February 2018

Responding to the announcement that NICE has approved Pertuzumab (Perjeta) for routine use on the NHS in England1, Samia al Qadhi, Chief Executive of...

1 February 2018

Responding to breast screening data released by NHS Digital Samia al Qadhi, Chief Executive of Breast Cancer Care, says: “In light of today’s...

31 January 2018

Responding to the decision by NICE today (Wednesday 31 January) to not recommend fulvestrant (Faslodex) for use by the NHS in England*, Samia al...

31 January 2018

Discussing NICE’s draft updated guideline on early and locally advanced breast cancer, Samia al Qadhi, Chief Executive of Breast Cancer Care,...

24 January 2018

Responding to a study that has found no association between night-time light levels and breast cancer risk, Rachel Rawson, Senior Clinical Nurse...

24 January 2018

Responding to the findings (published in the Journal of the National Cancer Institute) that screening the entire population for breast and ovarian...

18 January 2018

Responding to updated NICE draft guidance on breast cancer profiling tests Dr Emma Pennery, Clinical Director of Breast Cancer Care, says: “...

11 January 2018

Responding to the decision by NICE (on Thursday 14 December 2017) to not recommend fulvestrant (Faslodex) for use by the NHS in England*, Samia al...

19 December 2017